To evaluate the efficacy and safety of a new drug on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction ≥40% (LVEF ≥40%).
To be considered for the study you must meet the following criteria:
- Aged 40 years or older
- Patients with a diagnosis of HF, NYHA class II–IV, and documented LVEF of ³40%.
- On diuretic treatment for at least 30 days prior to study
Your participation in this study would be for approximately 3.5 years.
You are required to attend the clinic for an initial assessment where information on your health condition will be collected from you.
Eligible participants will be required to attend a series of visits alternating between in-clinic visits and telephone appointments. During some of these visits the dose of the study drug will be increased based on blood test results.
You will then be followed up 30 days post study completion.